NPI 1104904275: Open Payments
NPI 1104904275. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,192 in 53 payments from 19 companies in 2025. Trend: 2023 $1,385 · 2024 $1,270 · 2025 $1,192
Food & beverage: $1,192
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $159 |
| Novo Nordisk Inc | 7 | $135 |
| Lilly USA, LLC | 5 | $121 |
| PFIZER INC. | 5 | $109 |
| Collegium Pharmaceutical, Inc. | 5 | $104 |
| Exact Sciences Corporation | 3 | $76 |
| Verity Pharmaceuticals Inc. | 4 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $59 |
| Edwards Lifesciences Corporation | 1 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
Products named: Belbuca, NURTEC ODT, JARDIANCE, VRAYLAR, Tlando, Cologuard Collection Kit, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, Wegovy.
